SavedAdd your journal

Journals / Eurasian Journal of Biological and Chemical Sciences / 2022 / Cilt: 5 - Sayı: (Ek sayı 1)

Tamoxifen Delivery to Breast Cancer Cells (MCF-7) Via Hydroxyapatite Microspheres

Binnaz KIRBIYIK
Birgül MAZMANCI
Şeyma Gülnaz YARLILAR
Naz UĞUR
Kasım OCAKOĞLU
Pages
111–118
Publication Date
2022-12-30
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As a result, use of hydroxyapatite was suitable for the transport of TAM and that covalent binding was suitable for drug particle interaction with hybrid structure and thus controlled drug release occurred.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Drug delivery systems have been used in cancer treatment to increase drug effectiveness.
📊
Key Findings & Data:The breast cancer cell line MCF-7 was used to examine the effect of the hybrid structure.
💡
Conclusion & Impact:As a result, use of hydroxyapatite was suitable for the transport of TAM and that covalent binding was suitable for drug particle interaction with hybrid structure and thus controlled drug release occurred.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Hydroxyapatite microsphere · Tamoxifen · Hydrothermal method

Abstract

Drug delivery systems have been used in cancer treatment to increase drug effectiveness. The hydroxyapatite (HAP) based materials used in this area can provide drug transport to the target site without its deterioration. In this study, porous hollow hydroxyapatite microspheres (PHHMs) were produced by using the hydrothermal method. Tamoxifen (TAM) used in the treatment of breast cancer has been covalently attached to the produced microspheres. The obtained microsphere structures (tamoxifen-loaded hydroxyapatite, TAM/H) were successfully characterized by ATR-FTIR, FE-SEM, XRD, and DLS methods. The breast cancer cell line MCF-7 was used to examine the effect of the hybrid structure. The cytotoxic and genotoxic effects of TAM/H was compared with the TAM groups on MCF-7. Our results have showed that, the decrease in cell viability at 24 and 36 hours were still continued at 48 hours only in TAM/H groups. In addition, TAM/H was found to show a genotoxic affect by the increment in genetic damage index (GDI) and damaged cell percentage (DCP%). As a result, use of hydroxyapatite was suitable for the transport of TAM and that covalent binding was suitable for drug particle interaction with hybrid structure and thus controlled drug release occurred.

🔖

Cite This Article

KIRBIYIK, B., MAZMANCI, B., YARLILAR, Ş. G., UĞUR, N., OCAKOĞLU, K. (2022). Tamoxifen Delivery to Breast Cancer Cells (MCF-7) Via Hydroxyapatite Microspheres. Eurasian Journal of Biological and Chemical Sciences, Cilt: 5 - Sayı: (Ek sayı 1), 111–118. https://ajindex.com/articles/867997

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics. CA Cancer J for Clin. 2001. 51(1): 15-36.
  2. Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Targed Ther. 2018. 3:7. Yao Y, Zhou Y, Liu L, Xu Y, Chen Q, Wang Y, Wu S, Deng Y, Zhang J, Shao A. Nanoparticle-Based Drug Delivery in Cancer Therapy and Its Role in Overcoming Drug Resistance. Front. Mol. Biosci. 2020. https://doi.org/10.3389/fmolb.2020.00193.
  3. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. Nature Biotech. 2015. 33(9): 941-951.
  4. Singh SK, SinghS, Lillard JWJr, Singh R. Drug delivery approaches for breast cancer. Inter J Nanomed 2017. 12: 6205–6218.
  5. Haley B, Frenkel E. Nanoparticles for drug delivery in cancer treatment. Urologic Oncology: Seminars and Original Investigations. 2008. 26: 57–64.
  6. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Cont Rel. 2000. 65(1–2): 271–284. Allen TM. Ligand-targeted therapeutıcs in anticancer therapy. Nat Review Cancer. 2002. 2(10): 750-763.
  7. Jafari S, Adibkia K. Application of Hydroxyapatite Nanoparticle in the Drug Delivery Systems. J Mol Phar Org Pro Reserch. 2014. 03: 01. Hench LL, J. Wilson J. An Introduction to Bioceramics. World Scientific Publishing Co. 1993. 139-189. Pasinli A. Biyomedikal alanlarda kullanılan biyomalzemeler. Makine Teknolojileri Elektronik Dergisi. 2004. 4: 25-34.
  8. Netz DJA, Sepulveda P, Pandolfelli VC, Spadaro ACC, Alencastre JB, Bentley MVLB, Marchetti JM. Potential use of gelcasting hydroxyapatite porous ceramic as an implantable drug delivery system, International Journal of Pharmaceutics. 2001. 213(1-2): 117-125.
  9. Uskokovic V, Desai TA. In vitro analysis of nanoparticulate hydroxyapatite/chitosan composites as potential drug delivery platforms for the sustained release of antibiotics in the treatment of osteomyelitis. J Phar Sci. 2014. 103(2): 567-579.
  10. Andres NC, Sieben JM, Baldini M, Rodriguez CH, Famiglietti A, Messina PV. Electroactive Mg2+-Hydroxyapatite Nanostructured Networks against Drug-Resistant Bone Infection Strains. ACS Appl Mater Interfaces. 2018.
  11. Paganini-Hill A, Clark LJ. Preliminary assessment of cognitive function in breast cancer patients treated with tamoxifen. Breast Cancer Res Treat. 2000. 64(2): 165-7.
  12. Bender CM, Sereika SM, Brufsky AM, Ryan CM, Vogel VG, Rastogi P